On June 15, 2023, the inaugural meeting of Institute of Bioinformatics of Shanghai Academy of Experimental Medicine (hereinafter referred to as "Institute of Bioinformatics") and Gene Sequencing Bioinformatics Research Summit Forum was held in Intercontinental Hotel in Jing'an, Shanghai. Ltd. said in his speech that AutoBio, as the leading unit of Bioinformatics Institute, will focus on the research and transformation of the frontier technology of bioinformatics data and promote the integration of "industry-university-research-medicine" in the field of gene diagnosis with the mission of serving the clinic. He pointed out that Auto Biotech has laid out the NGS product line business for many years, established the R&D centers in Zhengzhou and Shanghai, and promoted the research of bio-information technology in clinical application with the integration of "gene + big data" technology as the grip, and has achieved positive R&D results.

The Institute of Bioinformatics of Shanghai Academy of Experimental Medicine is based on Shanghai Institute of Experimental Medicine, led by Auto Bio, and jointly established with top clinical academic teams, university institutions and biomedical companies in Shanghai and even in China, driven by "project funding, mutual participation and result sharing". It aims to establish a top-notch and world-class bioinformatics institute. In the future, Bioinformatics Institute will promote the research and application of bioinformatics data in clinical diagnosis and treatment, and will be a leading new bioinformatics research institute in China, which integrates basic research, product development and industrialization, and will contribute to the service of clinical and human health with rich research results.

About AutoBio:

Autobio Diagnostics Co., Ltd (Hereinafter called Autobio) was founded in 1998, headquartered in National Eco & Tech Zone, Zhengzhou.

Autobio specialized in R & D, production, marketing and service of clinical diagnostic products, especially covering immunoassay, microbiology and biochemistry fields. Meanwhile, Autobio is also actively planning the developments in the field of molecular diagnostics and provides a comprehensive solutions for medical laboratories. Autobio was listed on Shanghai Stock Exchange on September 1st, 2016, which is the first IVD manufacturer listed on the main board in Shanghai, China. In 2019, Autobio’s revenue achieved USD412 millions, a year-on-year increase of 38.85%; in 2020, Autobio’s revenue achieved USD459 millions.